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Characterization of resistance to a potent 
d-peptide HIV entry inhibitor
Amanda R. Smith1†, Matthew T. Weinstock1†, Amanda E. Siglin2, Frank G. Whitby1, J. Nicholas Francis1, 
Christopher P. Hill1, Debra M. Eckert1, Michael J. Root2 and Michael S. Kay1* 
Abstract 
Background: PIE12-trimer is a highly potent d-peptide HIV-1 entry inhibitor that broadly targets group M isolates. 
It specifically binds the three identical conserved hydrophobic pockets at the base of the gp41 N-trimer with sub-
femtomolar affinity. This extremely high affinity for the transiently exposed gp41 trimer provides a reserve of binding 
energy (resistance capacitor) to prevent the viral resistance pathway of stepwise accumulation of modest affinity-
disrupting mutations. Such modest mutations would not affect PIE12-trimer potency and therefore not confer a 
selective advantage. Viral passaging in the presence of escalating PIE12-trimer concentrations ultimately selected for 
PIE12-trimer resistant populations, but required an extremely extended timeframe (> 1 year) in comparison to other 
entry inhibitors. Eventually, HIV developed resistance to PIE12-trimer by mutating Q577 in the gp41 pocket.
Results: Using deep sequence analysis, we identified three mutations at Q577 (R, N and K) in our two PIE12-trimer 
resistant pools. Each point mutant is capable of conferring the majority of PIE12-trimer resistance seen in the poly-
clonal pools. Surface plasmon resonance studies demonstrated substantial affinity loss between PIE12-trimer and the 
Q577R-mutated gp41 pocket. A high-resolution X-ray crystal structure of PIE12 bound to the Q577R pocket revealed 
the loss of two hydrogen bonds, the repositioning of neighboring residues, and a small decrease in buried surface 
area. The Q577 mutations in an NL4-3 backbone decreased viral growth rates. Fitness was ultimately rescued in resist-
ant viral pools by a suite of compensatory mutations in gp120 and gp41, of which we identified seven candidates 
from our sequencing data.
Conclusions: These data show that PIE12-trimer exhibits a high barrier to resistance, as extended passaging was 
required to develop resistant virus with normal growth rates. The primary resistance mutation, Q577R/N/K, found in 
the conserved gp41 pocket, substantially decreases inhibitor affinity but also damages viral fitness, and candidate 
compensatory mutations in gp160 have been identified.
Keywords: HIV entry inhibition, d-peptide, PIE12-trimer, gp120, gp41, Viral resistance mutation, Hydrophobic pocket, 
Viral fitness, Compensatory mutation, Viral passaging
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Background
Approximately 37 million people are living with Human 
Immunodeficiency Virus (HIV), a virus that has resulted 
in an estimated 35 million deaths due to Acquired Immu-
nodeficiency Syndrome (AIDS) [1]. Combination anti-
viral therapeutics targeting various stages of the viral 
lifecycle have dramatically improved the clinical outcome 
for those with access to treatment, but viral resistance 
has been documented for all approved drugs [2]. This 
resistance is facilitated by a high mutation rate (due to a 
low-fidelity viral reverse transcriptase, frequent recom-
bination events, rapid turnover of the virus, and host 
APOBEC3 activity) in the face of the selective pressure of 
the drug [3–5].
We previously reported the discovery and design 
of an extremely potent d-peptide HIV-1 entry inhibi-
tor (PIE12) that targets the HIV envelope protein (Env) 
using sequential rounds of mirror-image phage display 
and high-resolution structure-guided design [6–9]. With 
the opposite chirality of naturally occurring l-peptides, 
d-peptides (composed of d-amino acids) are not recog-
nized by natural proteases. This property confers longer 
in vivo half-lives and reduced immunogenicity, which are 
potentially significant therapeutic advantages [7]. The 
target of PIE12 is the highly conserved pocket at the base 
of the gp41 N-trimer, a parallel trimeric coiled-coil region 
of gp41 that is transiently exposed (“prehairpin interme-
diate”) during HIV-1 entry. The N-trimer pocket is an 
appealing antiviral target due to its high conservation, 
extracellular accessibility, and its vital role in viral entry. 
Our inhibitor harnesses avidity for this trimeric pocket, 
as three d-peptide monomers are covalently linked via an 
optimized PEG-based scaffold (PIE12-trimer), and binds 
the N-trimer with sub-fM affinity [8, 10]. PIE12-trimer 
prevents the folding of the N-trimer and C-peptide 
regions of gp41 into the 6-helix bundle (trimer-of-hair-
pins) structure required for membrane fusion during 
viral entry, and it inhibits all members of a diverse panel 
of primary Group M HIV isolate strains with high pM to 
low nM potency  (IC50) [8].
The remarkable conservation of this gp41 hydropho-
bic pocket target [6] is indicative of its critical roles in 
the viral life cycle and impedes the ability of the virus 
to combat inhibitors that target it. The region of the 
HIV-1 genome encoding the pocket is conserved at 
both the protein level (for the role of gp41 in membrane 
fusion during viral entry) and nucleotide level (due to a 
structured RNA region in the critical Rev-response ele-
ment). The only FDA-approved HIV fusion inhibitor, 
enfuvirtide (Fuzeon), is an l-peptide derived from the 
gp41 C-peptide region that targets the gp41  N-trimer 
region adjacent to, but not including, the hydropho-
bic pocket and induces the rapid emergence of gp41 
resistance mutations both in vitro and in vivo [11, 12]. 
Next-generation l-peptide fusion inhibitors (such as 
T-1249 and T-2635), whose binding footprint extends 
into the pocket, are much less impacted by enfuvirtide 
resistance mutations. Viral escape from these inhibi-
tors generally takes longer to appear but still involves 
resistance mutations located outside the pocket region 
[13–16].
In addition to targeting a highly conserved, functionally 
critical region of the virus, PIE12-trimer was designed 
with an additional barrier to viral resistance called the 
“resistance capacitor”. The gp41  N-trimer is transiently 
exposed during HIV entry in a prehairpin intermediate 
conformation [17]. The potency of a variety of high-affin-
ity prehairpin intermediate-targeting inhibitors has been 
shown to vary with changes in association kinetics rather 
than affinity, reflective of the kinetically limited availabil-
ity of the target [8, 9, 18–20]. Once a threshold associa-
tion rate is reached, additional affinity enhancement fails 
to improve antiviral potency. We chose to “over-engi-
neer” PIE12-trimer such that its pocket-binding affinity 
far surpassed its potency. This excess binding energy, or 
resistance capacitor, should prevent the accumulation 
of incremental mutations that modestly disrupt inhibi-
tor affinity, as such mutations would not affect potency 
and would therefore fail to confer a selective replicative 
advantage. Instead, the virus would be forced to combat 
PIE12-trimer with a strongly disruptive mutation, likely 
at the cost of viral fitness.
Several lines of evidence suggested that PIE12-trimer 
would exhibit a high barrier to resistance. First, PIE12-
trimer is estimated to bind with sub-fM affinity and 
inhibit with low nM potency, characteristic of a “highly 
charged” resistance capacitor [8]. Second, PIE12-trimer 
exhibits higher potency against polyclonal viruses 
derived from infected patients than does an earlier gen-
eration d-peptide trimer with lower affinity, demonstrat-
ing its better tolerance of Env sequence variation. Finally, 
PIE12-trimer maintains potency against virus resistant to 
PIE7-dimer, a lower affinity d-peptide. Indeed, consistent 
with a “highly charged” resistance capacitor, we observed 
a significant delay in the selection of HIV-1 resistant to 
PIE12-trimer compared to selections against enfuvirtide 
and earlier-generation d-peptides [8].
Expanding on our earlier work that selected for viral 
resistance to PIE12-trimer, here we describe the bio-
chemical, structural, and functional properties of the pri-
mary PIE12-trimer resistance mutations (Q577R/N/K). 
These mutations substantially disrupt PIE12-trimer 
affinity and significantly decrease viral fitness. Through 
comprehensive characterization of the genotype of our 
PIE12-trimer resistant viral populations via next-gener-
ation sequencing, we identify potential compensatory 
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mutations in HIV Env that restore fitness in the context 
of Q577R/N/K.
Results
Primary resistance to PIE12‑trimer arises via mutation 
of Q577 in the gp41 hydrophobic pocket
We previously reported the selection of HIV-1 popu-
lations resistant to PIE12-trimer by passaging the 
lab-adapted NL4-3 strain in the presence of escalat-
ing suboptimal (partially inhibiting) concentrations of 
inhibitor, starting with 1  nM. Ultimately, PIE12-trimer 
resistant virus propagating in 320  nM PIE12-trimer 
was obtained after 65  weeks of passaging [8]. Duplicate 
selections yielded two highly resistant polyclonal viral 
pools (W1 and W2). As previously reported, similar pas-
saging studies with enfuvirtide led to high-level resist-
ance (> 1000-fold) within ~ 3  weeks [8]. Both W1 and 
W2 showed > 650-fold loss of sensitivity to PIE12-trimer 
while retaining full susceptibility to the C-peptide inhibi-
tor, C37, demonstrating the ability of the virus to spe-
cifically resist PIE12-trimer while maintaining the native 
interaction between the N-trimer and C-peptide (Fig.  1 
and Table 1).
Early analysis of a limited number of clones from the 
W2 resistant pool via Sanger sequencing identified the 
mutation Q577R within the gp41 hydrophobic pocket 
in all clones [8]. In an HXB2 pseudovirion, Q577R con-
fers > 4000-fold resistance to PIE12-trimer [10]. Here, 
to characterize the genetic basis of resistance and to 
understand the penetrance of the Q577R mutation, we 
deep sequenced the W1 and W2 viral pools, as well as a 
pNL4-3 control viral pool that had been propagated in 
the absence of inhibitors. This more extensive sequencing 
(with an average sequencing depth of > 200,000 reads per 
nucleotide position) revealed two distinct mutations at 
position Q577 (codon CAG) in the highly resistant pools: 
N (codon AAC) in W1 and R (codon CGG) in W2. Q577 
is mutated in virtually all of the resistant virus (> 97% of 
the sequences in W1 and W2), and there were no spon-
taneous Q577 mutations in the control population (Addi-
tional file  1). Additionally, there are no other positions 
within the gp41 pocket that are mutated.
Q577R only requires a single nucleotide change, while 
Q577N requires a double mutation and likely occurs 
stepwise. To determine which pathway the virus took 
to acquire the Q577N substitution, we deep sequenced 
this N-trimer region from an intermediate pool of virus 
isolated at an earlier timepoint during resistance selec-
tion and noted an equal ratio of N (AAC) and K (AAG) 
(data not shown). In the context of replication-competent 
virus (NL4-3 strain), each Q577 mutant (R, N or K) con-
fers substantial resistance to PIE12-trimer (~ 100-fold) 
and accounts for the majority of the loss of sensitivity to 
PIE12-trimer (Fig. 1 and Table 1).
Mutation of Q577 significantly decreases PIE12‑trimer 
affinity for the gp41 pocket
To determine the impact of Q577 mutation on PIE12 
binding affinity, Q577R was incorporated into an N-pep-
tide mimic (IZN36 [17]), and the interaction was ana-
lyzed via surface plasmon resonance (SPR). Because 
PIE12-trimer affinity is too tight to accurately measure 
via SPR [8], monomeric PIE12 was flowed over the IZN36 
(WT and Q577R) surfaces. The Q577R mutation results 
in a dramatic (~ 65-fold) weakening of the interaction 
between PIE12-monomer and the hydrophobic pocket 
(Q577R  KD = 2.0  µM vs. 0.031  µM for WT) (Fig.  2 and 
Additional file 2), corresponding to a 2.5 kcal/mol weak-
ening of the PIE12 interaction. Because our inhibitor is 
trimeric, we expect the impact on PIE12-trimer’s binding 
Fig. 1 Representative inhibitory curves of replication-competent 
NL4-3 (WT) and PIE12-trimer resistant viruses. The polyclonal viral 
pools (W1 and W2) show slightly enhanced resistance compared 
to clonal virus expressing Env with Q577 point mutations. 
Representative normalized data are shown from a single assay with 
triplicate measurements (error bars show standard error).  IC50 values 
of this representative data set are indicated in parentheses
Table 1 Inhibition of  replication-competent HIV-1 (NL4-3 
backbone)
Average  IC50 values for clonal NL4-3 (WT), PIE12-trimer 320 nM polyclonal 
resistant pools (W1 and W2), and Q577 point mutations in the NL4-3 
background. Values are averages of  IC50’s fit from two independent experiments 
with triplicate measurements. Standard deviations are shown in parentheses
ND not determined
PIE12‑trimer (nM) C37 (nM)
NL4-3 (WT) 1.33 (0.79) 11.2 (4.07)
W1 (resistant pool) 999 (176) 7.62 (2.18)
W2 (resistant pool) 894 (419) 14.9 (1.31)
Q577R 188 (63) ND
Q577 N 164 (105) ND
Q577K 128 (59) ND
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energy to be three times as great, corresponding to a 
geometric drop of binding affinity of  653 (or > 250,000). 
This large decrease in binding affinity is consistent with 
the prediction that an extremely disruptive mutation 
is required to overcome PIE12-trimer’s highly charged 
resistance capacitor.
Crystal structure of PIE12 in complex with the Q577R 
mutation
To understand the molecular basis of Q577R-induced 
resistance, monomeric PIE12 was crystallized in com-
plex with an HIV-1  N-trimer pocket mimic (IQN17 
[17]) with the Q577R substitution, and the structure 
was determined at 1.3 Å resolution (Table  2, PDB code 
6PSA). As in all previous d-peptide/IQN17 structures 
[6, 8, 9], IQN17 forms a continuous trimeric coiled 
coil with the d-peptide binding to the gp41 hydropho-
bic pocket region. When compared to each of our pre-
viously reported structures of PIE12 binding to WT 
IQN17 (PDB codes 3L35, 3L36, and 3L37) [8], the overall 
structure agrees well, with root mean square deviations 
(RMSD) of ≤ 1.0 Å for all Cα atoms. A representative 
overlay of the mutant and WT structures (using 3L37, 
the WT structure with the lowest RMSD, 0.34  Å), cen-
tered around position 577 of the hydrophobic pocket is 
shown in Fig.  3. In the WT structure, Q577 hydrogen 
bonds with d-Glu9 and d-Trp12 in PIE12 [8]. Q577R dis-
rupts these hydrogen bonds, likely accounting for the loss 
of affinity, and induces a repositioning of two adjacent 
residues (d-Glu9 in PIE12 and L581 in IQN17, although 
d-Glu9 position is variable in the WT structures). These 
structural changes lead to a minimal change in the buried 
surface area of the inhibitor interface with the N-trimer 
target (555 and 524 Å2 in the WT and mutant structures, 
respectively). 
Mutation of Q577 causes a significant viral growth defect
The extended time required for evolution of high-level 
PIE12-trimer resistance in passaging studies (65 weeks) 
and the high sequence conservation of the inhibitor 
binding site on gp41 suggest that the primary Q577 
resistance mutations come with a fitness cost to the 
virus. We therefore investigated the growth kinetics 
of the NL4-3-based replication competent Q577 point 
mutants and the polyclonal viral pools (W1 and W2) 
and compared them to that of the native virus (clonal 
NL4-3, WT). Starting with a virus inoculum contain-
ing 1 ng p24, indeed, the growth of the Q577 mutants 
is significantly decreased compared to WT (Fig.  4). 
Q577R and Q577K did not propagate significantly dur-
ing the entire course of the assay, while Q577N repli-
cation was substantially delayed. Interestingly, the 
PIE12-trimer resistant polyclonal pools (W1 and W2) 
show similar growth kinetics to WT virus, suggesting 
Fig. 2 Protein interaction analysis of Q577R mutation. SPR 
equilibrium binding data (in triplicate) for interaction between 
immobilized IZN36 (WT or Q577R) and PIE12 monomer. The 
calculated  KD values are 0.031 µM for WT and 2.0 µM for Q577R
Table 2 Crystallographic data and refinement statistics
Q577R
Data
 Processing software HKL2000
 Space group R3 (48.8, 48.8, 67.6)
 Resolution (Å) 50.0–1.30
 Resolution (Å) (high-resolution shell) (1.35–1.30)
 # Reflections measured 144,573
 # Unique reflections 14,571
 Redundancy 9.9
 Completeness (%) 98.5 (99.7)
  < I/σI> 7 (2.1)
 CC1/2 0.985 (0.973)
 Mosaicity (o) 0.62
 Rpim 0.038 (0.128)
Refinement
 Refinement software PHENIX.REFINE
 Resolution (Å) 50.0–1.30
 Resolution (Å)—(high-resolution shell) (1.347–1.300)
 # Reflections used for refinement 14,461
 # Reflections in Rfree set 1445
 Rcryst 0.190 (0.249)
 Rfree 0.240 (0.282)
 RMSD: bonds (Å)/angles (°) 0.008/1.044
  < B > (Å2): all protein atoms/# atoms 23.9/530
  < B > (Å2): solvent molecules/#water + 2 chloride 
ions
40.7/76
 φ/ψ most favored (%)/additionally allowed (%) 100/0.0
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that compensatory mutations rescue the fitness defect 
associated with the Q577 mutants. WT, W1, and W2 
all show rapid growth and hit similar peak p24 levels. 
Importantly, starting viral titers of the Q577 mutant 
stocks (normalized to p24) vary significantly from WT, 
ranging from greatly reduced (~ 40-fold for Q577K 
and ~ 7-fold for Q577R) to increased (~ threefold for 
Q577N). Additionally, although the output viral popu-
lation was not sequenced, it is possible the Q577N 
sample regained replication fitness by reverting to WT 
during the course of the assay since it was not under 
the selective pressure of PIE12-trimer.
Identification of potential compensatory mutations 
to overcome the Q577 fitness defect
To identify additional mutations that arose during the 
selection for resistance, the entire env gene for each 
resistant pool (and control pool propagated in the 
absence of inhibitor) was deep sequenced. To comple-
ment these short reads and obtain linkage information, 
we also performed Sanger sequencing on 13 PIE12-
trimer resistant clones (five from W1 and eight from 
W2). This search should identify mutations that compen-
sate for the fitness defects associated with Q577R/N/K as 
well as those that contribute modestly to PIE12-trimer 
resistance, as W1 and W2 are slightly more resistant than 
the Q577 mutants alone (Fig. 1 and Table 1).
Using the deep sequencing data, we identified all point 
mutations, insertions, and deletions within the env gene 
of the PIE12-trimer resistant populations with > 10% 
absolute difference in abundance from the control pool 
(Table 3 and Additional file 1). We predict that 10% is a 
high enough threshold to filter out noise due to genetic 
drift and sequencing errors, but low enough to catch 
minor variations in the population that could contribute 
to resistance. Following these guidelines, 25 candidate 
protein mutations (74 env nucleotide positions) were 
identified for further analysis.
To focus our analysis on a more limited set of muta-
tions most likely to contribute to resistance and fit-
ness compensation, we narrowed our list to the those 
that were not silent (except in the Rev Response Ele-
ment (RRE), where a silent mutation could impact RNA 
structure) and with the highest penetrance (> 50% abun-
dance in both resistant viral pools but not in the control). 
Eight mutations meet these criteria (indicated in italics 
in Table  3). Interestingly, when we compared the clonal 
Fig. 3 Crystal structures of PIE12/IQN17 (Q577R) (PDB: 6PSA) and PIE12/IQN17 (WT PDB:3L37). Stereoview of the overlay of crystal structures of 
PIE12 binding to the WT (yellow) and a mutant (Q577R, turquoise) pocket showing the disruption of hydrogen bonding interactions mediated by 
Q577
Fig. 4 Viral Growth Assays. Comparison of growth kinetics between 
control clonal NL4-3 (WT), Q577 mutant viruses (R, N and K), 
and resistant polyclonal viral pools (W1 and W2). Viral titers were 
determined by qRT-PCR and compared to a standard curve of 
known HIV-1 titers (based on p24 antigen levels). Each culture was 
inoculated with virus containing 1 ng p24 (average of biological 
duplicate assays shown with s.d. error bars)
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Sanger sequence data to these final mutations of interest, 
all but one are present in every clone. Only A48T lacked 
100% penetrance and was found in 3/5 W1 and 3/8 W2 
clones.
In addition to identifying the primary resistance muta-
tion (Q577R/N/K) in the PIE12-trimer binding site, this 
analysis identified three gp120 and four gp41 mutations 
(Table  3 and Fig.  5). Of the gp120 mutations, one is a 
point mutation (A48T), and two are in-frame deletions 
(Δ161–164 in the V1/V2 loop and Δ396–400 in the V4 
loop). The V4 loop deletion truncates a tandem dupli-
cation of 5 amino acids (FNSTWFNSTW), with only 
one FNSTW copy linked with PIE12-trimer resistance. 
This deletion has also been reported in a virus resistant 
to T-2635, a third-generation C-peptide fusion inhibi-
tor [15]. The four gp41 mutations are all located out-
side the PIE12 binding site. Two (Q550H and the silent 
V583V) are located within the RRE, L663F is in the gp41 
membrane-proximal external region (MPER), and A823V 
is in the cytoplasmic domain between LLP-3 and LLP-1.
Discussion
This study identifies Q577R/N/K within the 
gp41 N-trimer hydrophobic pocket as the primary resist-
ance mechanism used to escape inhibition by the highly 
potent d-peptide entry inhibitor PIE12-trimer. As pre-
dicted by the resistance capacitor hypothesis, the selec-
tion for high-level resistance required: (1) extended 
passaging compared to those against earlier-generation 
entry inhibitors, (2) a mutation that dramatically reduced 
inhibitor affinity at the cost of substantially reduced 
viral fitness, and (3) compensatory mutations to restore 
viral fitness in the face of such a destabilizing mutation. 
Despite these obstacles, HIV-1 was ultimately able to 
resist PIE12-trimer in vitro.
Table 3 Amino acid changes in HIV-1 Env in polyclonal viral pools with high-level PIE12-trimer resistance
List of amino acid mutations (point mutant, insertion or deletion) in either resistance pool that occurs at a rate > 10% different than in the control pool. In italic are the 
mutants that meet the stricter criteria of: (1) high prevalence (≥ 50%) within both resistant populations but not in the control, (2) not silent (except in the RRE, where a 
silent mutation could impact RNA structure)
Mutation Codon Prevalence
Control (%) W1 (%) W2 (%) Notes
T19I acc → atc 44
A48T gca → aca 72 57
E83K gaa → aaa 32 20 10
N136D aat → gat 99 99 glycosylation site
N136K aat → aag 47
R146K aga → aaa 18 24
Δ161–164 90 90 V1/V2, glycosylation site
F175L ttc → ctc 67 V1/V2
V200E gtc → gaa 67
V255A gta → gca 46
N301K aac → aaa 71 100 99 glycosylation site
S306R agt → aga 64 20 V3
T319A aca → gca 85
Δ396–400 58 59 V4, glycosylation site
N460I aat → att 17 near CD4 binding site
G464E ggg → gag 82 glycosylation site
S465P tcc → ccc 11
Q550H cag → cac 92 98 N-trimer, RRE
Q577R cag → cgg 99 PIE12 binding site, RRE
Q577N cag → aac 97
V583V gtg → gta 100 100 silent/RRE
A612T gct → act 13 glycosylation site, RRE
H643Y cac → tac 99 46 97 C-peptide
L663F tta → ttt 99 99
N674T aac → acc 56 glycosylation site
V693I gta → ata 21
A823 V gct → gtt 98 99
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Interestingly, even though the gp41 hydrophobic 
pocket is highly conserved, in rare cases HIV-1 naturally 
accommodates alternate residues at position Q577. For 
example, the uncommon Group O HIV-1 strains (< 1% of 
global HIV-1 infections) primarily contain Q577R. Not 
surprisingly, we previously observed high-level PIE12-
trimer resistance in two HIV-1 Group O isolates [8]. 
Additionally, within the > 50,000 non-Group O sequences 
from the Los Alamos HIV Sequence Database, ~ 1.4% 
contain Q577R.
Q577R has also been identified in viral resistance 
screens against other HIV-1 entry inhibitors that target 
the prehairpin intermediate. Against N-trimer peptides 
N44, N36, and IZN36, the C-peptide T2635, and the ret-
rocyclin RC-101, Q577R is found in some [15, 21, 22] or 
all [23, 24] of the resistant viruses and always accompa-
nied by other gp41 mutation(s). By itself, Q577R provided 
only modest resistance to the N-trimer and C-peptide 
inhibitors (< threefold) [15, 24]. Viral escape from a 
recently identified adnectin, 6200_A08, which simi-
larly targets the gp41 hydrophobic pocket, has also been 
shown to use Q577R as the primary mechanism [25]. 
Consistent with our results, many of these studies have 
demonstrated a fitness defect for Q577R [15, 23–25]. 
Importantly, Q577R Env (HXB2 strain) has been shown 
to be properly expressed, processed, and incorporated 
into pseudovirions, so the fitness defect is likely down-
stream of virus production [26]. Surprisingly, genetic 
analysis of the virus from a patient resistant to the FDA-
approved peptide fusion inhibitor enfuvirtide also identi-
fied the Q577R mutation [27], and in the context of that 
patient’s pre-treatment env, provided 25-fold resistance 
to enfuvirtide. This discovery is an outlier, however, as 
the primary resistance mechanism to enfuvirtide involves 
mutation within gp41 residues 547–556 [11], and the 
enfuvirtide sensitivity of other studied HIV-1 strains is 
minimally affected by Q577R [15, 22–24]. Indeed, our 
data demonstrate only modest differences in C-peptide 
inhibition of Q577R compared to WT pseudoviruses, 
including C34, T20 (enfuvirtide) and T1249 (Additional 
file 3), and our PIE12-trimer resistant pools retain sensi-
tivity to a related peptide, C37 (Table 1).
The Q577 mutation in the critical N-trimer region 
could conceivably influence multiple stages of the entry 
process, leading to its effect on viral fitness. Using mul-
tiple methods, Weiss, et  al. have investigated the effect 
of Q577R on Env structure and function. They have 
shown that the Q577R substitution leads to: (1) a more 
stable  6-helix bundle structure, (2) greater neutraliza-
tion sensitivity to CD4 mimetics, and (3) decreased sus-
ceptibility to CD4-induced gp41 conformational changes 
that lead to viral inactivation [21, 22, 24, 28]. This wide 
influence of Q577 mutation on Env function supports the 
concept that both gp120 and gp41 modifications would 
be needed to restore viral fitness, as is seen in our PIE12-
trimer resistant pools. However, there is little overlap 
between the Env modifications seen in our pools and 
those in naturally occurring strains with Q577R and in 
Q577R virus resistant to other entry inhibitors. As shown 
in an alignment of the ~ 750 Group M primary isolate 
Q577R Envs (out of > 50,000 Group M sequences from 
the Los Alamos HIV Sequence Database) with our PIE12-
trimer resistant sequences, none of the candidate PIE12-
trimer-resistant compensatory mutations are prevalent in 
the primary isolates (Additional file  4). Additionally, we 
did not identify any overlap of our specific compensatory 
Fig. 5 Prominent mutations in gp120 and gp41 observed in PIE12-trimer resistant viruses. The primary structure of the Env precursor, gp160, is 
depicted, with HXB2 (UniProtKB P04578) numbering. The gp41 N- and C-peptide regions are numbered according to [45]. gp160 is processed into 
two non-covalently associated subunits, the surface gp120 (orange) and the membrane-spanning gp41 (blue). gp120 comprises five constant 
domains (C1–C5) and five variable domains (V1-V5). gp41 contains a fusion peptide (FP), an N-peptide region that forms the N-trimer coiled coil (N), 
a C-peptide region (C) that together with the N-trimer forms a 6-helix bundle in the post-fusion state, a membrane-proximal external region (MPER), 
a transmembrane domain (TM), and a cytoplasmic tail (CT). The primary resistance mutations (Q577R/N/K) are represented in red, and candidate 
resistance and fitness compensation mutations are shown in black. Mutations denoted by * are within the Rev Response Element (RRE)
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mutations with those found in the other entry-inhibitor 
resistance screens with Q577R virus [15, 22–24].
Although none of our specific compensatory mutations 
are found in Q577R viruses resistant to other entry inhib-
itors, it seems likely that similar compensation mecha-
nisms are used. In previous entry inhibitor resistance 
studies that include Q577R and for which gp120 sequence 
is available [15, 21–23, 28], compensatory mutations are 
found in CD4 binding residues (E426K), the V1/V2 loop 
(D167N), and in the V3 loop (R298K, S306G, I309M, 
T319I, and E322D), indicating that changes to gp120-
based fusion determinants, such as CD4 and co-receptor 
binding, help restore gp41-based fitness defects. Our V1/
V2 and V4 loop deletions may similarly affect Env func-
tion. Additionally, several V3 loop mutants that are simi-
lar to those identified in other resistance selections were 
found in some of our sequences (S306R, T319A).
The region of the HIV genome that encodes the highly 
conserved hydrophobic pocket (the target of PIE12) 
also encodes part of the Rev-Response Element (RRE), 
whose specific RNA structure is required for proper 
viral replication. By analyzing nucleotide accessibility to 
chemical modification, Legiewicz et  al. [29] previously 
showed silent mutation at Q577 (codon CAG to CAA) is 
sufficient to induce structural changes in the RRE, spe-
cifically in stem loops III–V. Although our nucleotide 
sequences differ from that in the Legiewicz study (codon 
CGG for Q577R and AAC for Q577N), we similarly pos-
tulate an RRE structural rearrangement centered at the 
base of stem-loop V [30], the location of the 577 codon, 
that likely contributes to the fitness defect. Interestingly, 
Q550H and Q577R/N/K are observed in nearly all PIE12-
trimer resistant sequences. The presence of additional 
mutations within the RRE, namely Q550H and a silent 
mutation at V583(GTG→GTA), suggest these may play 
an important compensatory role in restructuring the 
RRE. Indeed, the structural rearrangement induced by 
Q577 mutation seen by Legiewicz was maintained with 
a silent mutation at Q550. However, Q550 mutations are 
not observed in any of the 689 Q577R-containing pri-
mary isolates (Additional file 4). Residue 583 is variable 
in the Q577R-containing primary isolates, although only 
hydrophobic residues (valine, isoleucine, leucine, and 
methionine) are observed.
Compensatory mutations to changes in the RRE could 
also be found in Rev, which binds the RRE to promote 
the export of mRNA from the nucleus. Although our 
sequence analysis focused on mutations in env, 80% 
of the Rev sequence (exon 2) is encoded within this 
same genomic region. Three Rev mutations (env posi-
tions 2354, 2375 and 2435, leading to N86Y, G93W, and 
G113R in Rev while silent in Env) surfaced in our ini-
tial analysis (Additional file  1), but each is present in 
only one resistant pool, none are fully penetrant, and all 
are located in the predicted disordered nuclear export 
sequence [31]. Sequencing of rev exon 1 and functional 
studies of mutant Rev/RRE will be required to see if there 
are any meaningful compensatory changes in Rev.
We have also sought to improve the overall potency 
and breadth of PIE12-trimer by conjugating it to choles-
terol (chol-PIE12-trimer) to concentrate it at cell mem-
brane lipid rafts, the site of viral entry. This modification 
increases its association rate for the prehairpin interme-
diate and improves potency ~ 100-fold [10]. Addition-
ally, cholesterol conjugation prolongs the in vivo half-life 
of the inhibitor, making it suitable for extended-release 
delivery [32]. With its improved potency, chol-PIE12-
trimer is better able to combat PIE12-trimer resistant 
virus and inhibits pseudovirions with the Q577R muta-
tion with a low nanomolar  IC50 [10]. However, our 
preliminary viral passaging studies in the presence of 
chol-PIE12-trimer suggest that high-level resistant virus 
ultimately emerges. Like for the PIE12-trimer resistant 
viruses, the pathway to resistance against chol-PIE12-
trimer includes mutation of Q577, and no other pocket 
mutations were observed. We are currently studying the 
additional mutations acquired during chol-PIE12-trimer 
passaging to understand the mechanism of resistance 
against this potential clinical candidate.
Ultimately, we hope to use the data described here to 
develop next-generation d-peptide inhibitors that antici-
pate this route of resistance to create an even higher bar-
rier to resistance. Efforts are underway to discover novel 
d-peptide entry inhibitors that maintain high affinity to 
both the native and Q577R pockets.
Conclusion
Although our highly potent, broad d-peptide entry inhib-
itor, PIE12-trimer, exhibits a high barrier to resistance, 
with extended passaging (> 1 year) we eventually obtained 
HIV-1 resistant to PIE12-trimer. The primary resistance 
mutation, Q577R/N/K, is found in the conserved PIE12-
trimer binding pocket on the gp41 N-trimer. Q577R dis-
rupts two hydrogen bonds between PIE12-trimer and 
the inhibitor-binding pocket and substantially decreases 
binding affinity. Q577 mutation confers a significant fit-
ness defect as seen by delayed viral replication. The 
highly resistant polyclonal viral pools exhibit rescued 
fitness due to compensatory mutations found in gp120 
and gp41. Using deep sequencing analysis, we identified 
seven potential compensatory mutations, which will be 
the focus of future mechanistic studies. Possible compen-
satory mechanisms include modifications to viral entry 
steps, such as receptor and co-receptor binding, fusion 
kinetics, Env folding, and interactions between Rev and 
the RRE.
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Methods
Passaging studies
PIE12-trimer resistant viruses were acquired in a pre-
vious study [8]. Briefly, CEM-1 cells were infected with 
the laboratory-adapted HIV-1 strain NL4-3 (obtained 
from Dr. Malcolm Martin, Cat #114, NIH AIDS Rea-
gent Program). Virus was serially propagated weekly 
by adding a 1:5 dilution of cell-free viral supernatant to 
fresh CEM-1 cells in the presence or absence (control) 
of PIE12-trimer. Viral titers were monitored biweekly by 
p24 antigen ELISA (PerkinElmer). The initial inhibitor 
concentration was 1  nM (near the PIE12-trimer  IC50). 
When p24 antigen levels in PIE12-trimer-containing cul-
tures approached the level seen in inhibitor-free (control) 
cultures (typically 5–15  weeks), PIE12-trimer concen-
trations were raised approximately 1.5- to 2-fold. Ulti-
mately, two polyclonal viral pools able to propagate in 
the presence of 320 nM PIE12-trimer (W1 and W2) were 
obtained. These pools were propagated in CEM-GFP 
cells for 48 h then isolated and concentrated over a 20% 
sucrose cushion.
Cells and viruses
TZM-bl cells that express luciferase and β-galactosidase 
in response to HIV-1 promoter activation (obtained 
from Dr. John C. Kappes and Dr. Xiaoyun Wu, Cat 
#8129, NIH AIDS Reagent Program) and 293T cells were 
grown in Dulbecco’s modified Eagle media. CEM-GFP 
cells that express GFP in response to HIV-1 LTR acti-
vation (obtained from Dr. Jacques Corbeil, Cat #3655, 
NIH AIDS Reagent Program) were grown in RPMI 1640 
media. The Q577R, Q577N and Q577K point mutant 
viral vectors were generated by excising the env region 
of the WT pNL4-3 genome using XhoI and EcoRI (NEB) 
and ligating into pET20b (Novagen), a shuttle vector 
we used for mutagenesis. The point mutants (CGG for 
Q577R, AAG for Q577K and AAC for Q577N) were 
introduced using the Q5 site-directed mutagenesis kit 
with primers designed using NEBuilder software (NEB). 
The Q577R forward and reverse primers were CAA 
ACA GCT CCG GGC AAG AATCC and ATG CCC CAG 
ACT GTG AGT T. The Q577N forward and reverse prim-
ers were CAA ACA GCT CAA CGC AAG AAT CCT GG 
and ATG CCC CAG ACT GTG AGT . The Q577K forward 
primer was CAA ACA GCT CAA GGC AAG AATCC, 
and the reverse primer was the same as that for Q577N. 
Mutated clones were confirmed by Sanger sequencing, 
and the desired mutants were ligated back into the WT 
pNL4-3 backbone after EcoRI/XhoI digestion. Env in the 
final Q577-mutated pNL4-3 constructs was confirmed by 
Sanger sequencing. These vectors were then transfected 
into 293T cells using Fugene HD (Promega) to generate 
replication-competent virus. Viral titers were measured 
using the HIV-1 p24 Antigen Capture Assay (Advanced 
Bioscience Laboratories) and confirmed by X-gal staining 
of infected TZM-bl cells.
Generation of envelope cDNA for Sanger and deep 
sequencing
Viral RNA was isolated from the W1, W2, and control 
viral pools with the E.Z.N.A.® Viral RNA Kit (Omega Bio-
Tek). Env cDNA was generated using the  SuperScript® 
III One-Step RT-PCR System with  Platinum® Taq High 
Fidelity (Invitrogen). Barcoded primers were designed 
using Primer3Plus (RT Primer: GCC TTG CCA GCA 
CGC TCA GGC CTT GCA TAG TAGCNNNNNNNNATG 
AGA GTG AAG GAG AAG TAT CAG C and PCR primer 
FWD: GCC TTG CCA GCA CGC TCA GGC) [33]. For 
Sanger sequencing, the env cDNA was cloned into stand-
ard vectors via two strategies. First pEBB backbone was 
used with NotI/XhoI sites. For increased efficiency, we 
also used TOPO cloning. Individual plasmid clones were 
sequenced by the DNA Sequencing Core Facility (Uni-
versity of Utah).
For deep sequencing, the cDNA was purified by aga-
rose gel electrophoresis, extracted (GenElute™ Gel 
Extraction Kit, Sigma), and submitted to the High-
Throughput Genomics and Bioinformatic Analysis Core 
Facility (Huntsman Cancer Institute, University of Utah) 
for library preparation and sequencing. Barcoded sam-
ples were multiplexed in a single lane and sequenced on 
an Illumina HiSeq 2000 (50 cycle single-end reads). The 
raw sequencing reads in FASTQ format were mapped to 
nucleotides 6195–8826 from the HIV-1 vector pNL4-3 
sequence (GenBank: AF324493.2) using STAMPY [34]. A 
summary of base calls for each position of the reference 
sequence was generated by converting the alignment 
data to pileup format using the SAMtools:mpileup func-
tion (used -BQ0 and -d 2,000,000 options). Custom Perl 
scripts were used to convert base calls at each position 
from pileup format to a more intuitive table and then to 
filter the data to display only those positions where devia-
tions from the reference are present in the population 
above a user-defined threshold (10%).
Peptide synthesis
All synthetic peptides were acetylated at the N-terminus 
and amidated at the C-terminus. All reverse-phase HPLC 
(RP-HPLC) purifications were performed on a Waters 
C18 column (BEH X-Bridge, 19 × 250  mm, 10  µm, 300 
Å) with water/acetonitrile gradient in 0.1% TFA unless 
otherwise noted. KG-PIE12 was synthesized by the Uni-
versity of Utah DNA/Peptide Core as described in [8] 
and purified via RP-HPLC on a Vydac C18 column (TP, 
22 × 250  mm, 10  µm, 300 Å). PIE12-GK and PIE12-
trimer were synthesized as previously described [8]. 
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SelMet-IQN17-Q577R and HIV C34 were synthesized 
on a PS3 peptide synthesizer (Protein Technologies, 
Inc.) at 80 µmol scale on NovaPEG Rink Amide LL resin 
(Novabiochem) and Rink Amide AM resin LL (Novabio-
chem), respectively, via Fmoc-SPPS and were purified by 
RP-HPLC.
Recombinant protein production
Cys-Gly-Gly-Asp-IZN36 (derived from HXB2 strain) 
with a thrombin-cleavable His tag was prepared as pre-
viously described [8]. A Q577R mutant version was 
generated via site-directed mutagenesis using the 
 QuikChange® protocol (Stratagene). Protein expression 
was performed in BL21 (DE3) cells (Novagen) following 
Studier’s autoinduction protocol [35]. Inclusion bodies 
containing IZN36 were solubilized in 20  mM sodium 
phosphate pH 8.0, 300 mM NaCl, 10 mM imidazole, 6 M 
GuHCl, and sonicated. IZN36 was then purified using 
His-Select Ni-affinity resin (Sigma). Ni-purified samples 
were dialyzed into water with 0.1% TFA and purified 
via RP-HPLC on a Waters C18 column (BEH X-Bridge, 
19 × 250 mm, 10 µm, 300 Å) with water/acetonitrile gra-
dient in 0.1% TFA and lyophilized. The cysteine residues 
of these constructs were biotinylated for SPR. Reactions 
were carried out in PBS pH 7.0 with ~ 1–2 mg/mL protein 
and a 15X molar excess of Biotin-dPEG®3-MAL (Quanta 
BioDesign) at room temp for 1 h, followed by RP-HPLC 
purification. The His tag was cleaved in PBS pH 6.3 with 
10  µM heparin at a protein concentration of ~ 0.8  mg/
mL and one unit of thrombin protease (GE Healthcare) 
per mg of protein. The cleavage reaction was incubated 
at 37 °C with agitation for 44 h followed by RP-HPLC as 
above.
Surface plasmon resonance analysis
Protein interaction analysis was carried out on a Biacore 
3000 (GE Healthcare). Analyses were performed in trip-
licate at 25  °C in sterile-filtered and degassed  Gibco® 
PBS pH 7.4 (Invitrogen) supplemented with 0.005% P20 
and 1  mg/mL BSA at a flow rate of 50  μL/min. First, 
streptavidin (Pierce) was immobilized on CM5 chips 
(GE Healthcare) using the Amine Coupling Kit (GE 
Healthcare) following a standard coupling protocol [36]. 
Stocks (~ 50 nM) of biotinylated IZN36 (WT and Q577R 
mutant) were prepared in running buffer in the pres-
ence of 1.2x molar excess of HIV C34 and captured on 
the surface to a density of 100–200 RUs. Loading IZN36 
in the presence of C34 results in better behaved surfaces, 
and C34 was removed by surface regeneration with 0.1% 
SDS injections. The active surface and a streptavidin-
derivatized control surface were blocked with d-biotin. 
Stock solutions of PIE12-GK were prepared at 50 μM in 
running buffer, from which samples in the concentration 
series were generated by serial dilution (three-fold to 
2.54  nM). Injections were performed for 1  min using 
KINJECT. Dissociation was monitored for 2  min, fol-
lowed by a 20 μL injection (QUICKINJECT) of running 
buffer followed by EXTRACLEAN. Sensorgrams were 
processed using Scrubber2 (BioLogic Software), and 
data were analyzed with Prism 5.0 (GraphPad Software). 
The equilibrium binding data were fit using the built-in 
saturation binding model (one site—specific binding), 
normalized to Bmax, and replotted as concentration of 
analyte vs.  % capacity.
Crystallography
KG-PIE12 was crystallized in complex with Se-Met-
IQN17-Q577R (1:1.1 IQN17:KG-PIE12, 10  mg/mL total 
in water) at 21 °C in Hampton Research condition SaltRx 
HT B4 (1.8 M ammonium citrate dibasic, 0.1 M sodium 
acetate trihydrate, pH 4.6) by sitting-drop vapor diffu-
sion. Several crystals were mounted in nylon loops and 
cryocooled following a 20 s immersion in 20 μL crystal-
lization buffer with 0–10% added glycerol. Data were 
collected from a single crystal judged by integration 
of test images to produce the best diffraction. Crystals 
were maintained at 100  K during data collection. Data 
collection was performed at the Stanford Synchrotron 
Radiation Lightsource (SSRL) beam line 7-1. Data were 
processed using HKL2000 [37]. The IQN17-Q577R/
PIE12 structure was determined by molecular replace-
ment using PHASER [38] with PIE12-IQN17 (PDB struc-
ture  3L37) as the search model. The model was rebuilt 
using O [39] and COOT [40] and refined against a maxi-
mum-likelihood target function using PHENIX [41]. The 
structure was checked using the MolProbity program 
[42]. See Table  2 for crystallographic data and refine-
ment statistics. Buried surface area was calculated with 
the program Naccess V2.1.1 [43]. For compatibility with 
Naccess, the surface areas were calculated with the ACE 
and NH2 modified ends removed, and the names of the 
d-amino acid residues changed to their cognate l-amino 
acids, without changing the coordinates.
Growth assay
CEM-GFP cells were infected with 1  ng p24 of either 
clonal pNL4-3, one of the Q577 point mutant viruses, 
or one of the polyclonal viral pools (W1 or W2) with 
DEAE dextran (8 µg/mL) and incubated at 37 °C for 2 h. 
Cells were then pelleted (2000 x g, for 5  min), super-
natant was removed, and cells were resuspended in 
fresh media. Cells were incubated for 3  days, then the 
medium was changed every day for the next 7 days. Viral 
supernatant was collected on days 3, 5, 7, and 9 post-
infection, and RNA was extracted using E.Z.N.A.® Viral 
RNA Kit (Omega Bio-Tek). Viral levels were measured 
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by qRT-PCR (Lightcycler 480, Roche) with primers tar-
geting a conserved region of Gag and compared to a 
standard curve of samples with known quantities of p24.
Viral inhibition assays
Viral infectivity was measured as previously described 
[44], with the following changes. Replication-competent 
viruses were added to TZM-bl cells in the presence of a 
tenfold dilution series of PIE12-trimer (100 nM to 10 pM 
for WT virus, 100 µM to 10 nM for resistant virus, from 
PIE12-trimer stock in 50 mM HEPES pH 7.4) and 8 µg/
mL DEAE dextran. Medium was removed after 30 h, and 
cells were lysed with Glo Lysis buffer (Promega). Bright-
Glo luciferase substrate (Promega) was added and lumi-
nescence was measured (POLARstar Optima, BMG). 
TZM-bl cells exhibit significant background lumines-
cence, so uninfected wells were used for background 
subtraction. Luciferase activity was normalized to unin-
hibited controls, and  IC50 values were determined from 
a fit to a Langmuir equation: y = 1/(1 + [inhibitor]/IC50) 
weighted by the normalized standard error of replicates 
within an assay (with a minimum 1% error) using Prism 
7.04 (GraphPad).
Supplementary information
Supplementary information accompanies this paper at https ://doi.
org/10.1186/s1297 7-019-0489-7.
Additional file 1. Mutations observed in PIE12-trimer resistant viral pools. 
Env gene position (pNL4-3 numbering), reference base, and all base calls 
for control and PIE12-trimer resistance viral populations with a muta-
tion > 10% of the population (with percentage of the base calls for each 
position colored on a spectrum from low (light pink) to high (red)) are 
indicated. Additionally, the positions are annotated by their location in Env 
according to the following categories: known or putative glycosylation 
site (green), gp120 variable loops (gray), chemokine receptor (co-receptor) 
binding site (blue), rev-response element (dark gray), gp41 N-trimer 
(orange), gp41 C-peptide region (light blue), or the Rev coding region 
included within the env gene (yellow). Eighty-one positions were identi-
fied. Of these, 74 conform to our analysis criteria (found in the resistant 
pool(s) and > 10% different frequency than in the control pool). 
Additional file 2. SPR sensorgrams for PIE12 monomer binding to IZN36 
WT (left panel) or Q577R (right panel), processed in Scrubber2 (BioLogic 
Software) and used for the equilibrium fit shown in Fig. 2. Six threefold 
dilutions of PIE12 monomer (617 nM to 2.54 nM) were flowed over the WT 
surface, and ten threefold dilutions (50 µM to 2.54 nM) were flowed over 
the Q577R surface. The calculated  KD’s are 0.031 µM for WT and 2.0 µM for 
Q577R. 
Additional file 3. Effect of Q577R on C-peptide Inhibitors. Single-cycle 
viral infectivity assays in which HIV-1 HXB2 Env (WT and Q577R) pseudo-
typed HIV-1 with a luciferase reporter was used to infect HOS-LES cells in 
the absence or presence of six fivefold dilutions of the indicated C-peptide 
(in quadruplicate). The data are the average of two experiments with the 
standard deviation in parentheses. 
Additional file 4. Prevalence of PIE12-trimer resistant candidate com-
pensatory amino acid mutations in Group M primary isolates containing 
Q577R.
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